Fundz
Real-time · AI · Cross-signal

Reviva Pharmaceuticals Holdings just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Reviva Pharmaceuticals Holdings, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
▶
Watch the 2-minute tour · with sound

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

Dec 17, 2024•over 1 year ago

Contract Type

partnership

CupertinoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Reviva Pharmaceuticals Holdings, Inc. announced the pricing of a public offering of 12,000,000 shares of common stock together with series A and B warrants. The company expects to receive aggregate gross proceeds of approximately $18.0 million from the offering.

Company Information

Company

Reviva Pharmaceuticals Holdings

Location

Cupertino, California, United States

About

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Predictive Intelligence
Strategic

ML-powered predictions for Reviva Pharmaceuticals Holdings's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.